AllianceBernstein’s Denali Therapeutics DNLI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $47.8M | Sell |
2,893,618
-664,317
| -19% | -$13.2M | 0.02% | 610 |
|
|
2025
Q4 | $58.7M | Buy |
3,557,935
+37,521
| +1% | +$633K | 0.02% | 574 |
|
|
2025
Q3 | $51.1M | Buy |
3,520,414
+383,274
| +12% | +$5.51M | 0.02% | 611 |
|
|
2025
Q2 | $43.9M | Sell |
3,137,140
-17,247
| -0.5% | -$243K | 0.01% | 638 |
|
|
2025
Q1 | $42.9M | Sell |
3,154,387
-161,255
| -5% | -$3.09M | 0.02% | 627 |
|
|
2024
Q4 | $67.6M | Buy |
3,315,642
+268,378
| +9% | +$6.87M | 0.02% | 514 |
|
|
2024
Q3 | $88.8M | Buy |
3,047,264
+1,028,730
| +51% | +$25.5M | 0.03% | 456 |
|
|
2024
Q2 | $46.9M | Buy |
2,018,534
+1,880,914
| +1,367% | +$36.1M | 0.02% | 611 |
|
|
2024
Q1 | $2.82M | Sell |
137,620
-2,340
| -2% | -$44K | ﹤0.01% | 1729 |
|
|
2023
Q4 | $3M | Buy |
139,960
+3,200
| +2% | +$63.4K | ﹤0.01% | 1723 |
|
|
2023
Q3 | $2.82M | Sell |
136,760
-41,960
| -23% | -$1.06M | ﹤0.01% | 1693 |
|
|
2023
Q2 | $5.27M | Buy |
178,720
+8,560
| +5% | +$241K | ﹤0.01% | 1409 |
|
|
2023
Q1 | $3.92M | Buy |
170,160
+15,200
| +10% | +$418K | ﹤0.01% | 1499 |
|
|
2022
Q4 | $4.31M | Hold |
154,960
| – | – | ﹤0.01% | 1498 |
|
|
2022
Q3 | $4.76M | Hold |
154,960
| – | – | ﹤0.01% | 1421 |
|
|
2022
Q2 | $4.56M | Hold |
154,960
| – | – | ﹤0.01% | 1494 |
|
|
2022
Q1 | $4.99M | Buy |
154,960
+300
| +0.2% | +$10.3K | ﹤0.01% | 1585 |
|
|
2021
Q4 | $6.9M | Hold |
154,660
| – | – | ﹤0.01% | 1446 |
|
|
2021
Q3 | $7.8M | Sell |
154,660
-700
| -0.5% | -$39.5K | ﹤0.01% | 1381 |
|
|
2021
Q2 | $12.2M | Buy |
155,360
+58,760
| +61% | +$3.64M | ﹤0.01% | 1135 |
|
|
2021
Q1 | $5.52M | Buy |
96,600
+700
| +0.7% | +$46.9K | ﹤0.01% | 1509 |
|
|
2020
Q4 | $8.03M | Buy |
95,900
+2,700
| +3% | +$163K | ﹤0.01% | 1236 |
|
|
2020
Q3 | $3.34M | Sell |
93,200
-2,200
| -2% | -$66.3K | ﹤0.01% | 1572 |
|
|
2020
Q2 | $2.31M | Buy |
95,400
+24,000
| +34% | +$564K | ﹤0.01% | 1764 |
|
|
2020
Q1 | $1.25M | Buy |
71,400
+400
| +0.6% | +$8.34K | ﹤0.01% | 1931 |
|
|
2019
Q4 | $1.24M | Hold |
71,000
| – | – | ﹤0.01% | 2186 |
|
|
2019
Q3 | $1.09M | Hold |
71,000
| – | – | ﹤0.01% | 2213 |
|
|
2019
Q2 | $1.47M | Buy |
71,000
+1,600
| +2% | +$35.9K | ﹤0.01% | 2138 |
|
|
2019
Q1 | $1.61M | Hold |
69,400
| – | – | ﹤0.01% | 2019 |
|
|
2018
Q4 | $1.43M | Buy |
69,400
+17,000
| +32% | +$308K | ﹤0.01% | 2015 |
|
|
2018
Q3 | $1.14M | Buy |
52,400
+27,000
| +106% | +$447K | ﹤0.01% | 2262 |
|
|
2018
Q2 | $387K | Buy |
+25,400
| New | +$479K | ﹤0.01% | 2707 |
|
Other funds holding DNLI
VCM
VPM
AllianceBernstein's DNLI Position: Q1 2026 in Review
AllianceBernstein reduced its Denali Therapeutics (DNLI) stake by 19% in Q1 2026, selling an estimated $13.2M and leaving 2,893,618 shares worth $47.8M. The position accounts for 0.02% of the portfolio, ranked #610.
AllianceBernstein first reported a position in DNLI in Q2 2018 and has held it in 32 quarters since. The position peaked at $88.8M in Q3 2024. 268 funds tracked by Wall St. Rank hold DNLI as of Q1 2026.
- AllianceBernstein held 2,893,618 shares of Denali Therapeutics worth $47.8M as of Q1 2026.
- AllianceBernstein sold 664,317 Denali Therapeutics shares in Q1 2026, an estimated $13.2M.
- Denali Therapeutics made up 0.02% of AllianceBernstein's portfolio in Q1 2026, its #610 holding.
- AllianceBernstein first reported a position in Denali Therapeutics in Q2 2018 and has held it in 32 quarters since.
- AllianceBernstein's Denali Therapeutics position peaked at $88.8M in Q3 2024.
- 268 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2026.
Based on AllianceBernstein's 13F filing for Q1 2026, filed 15 May 2026.